435 related articles for article (PubMed ID: 9428984)
1. In vitro activity of voriconazole against yeasts, moulds and dermatophytes in comparison with fluconazole, amphotericin B and griseofulvin.
Wildfeuer A; Seidl HP; Paule I; Haberreiter A
Arzneimittelforschung; 1997 Nov; 47(11):1257-63. PubMed ID: 9428984
[TBL] [Abstract][Full Text] [Related]
2. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin.
Wildfeuer A; Seidl HP; Paule I; Haberreiter A
Mycoses; 1998; 41(7-8):309-19. PubMed ID: 9861837
[TBL] [Abstract][Full Text] [Related]
3. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of voriconazole against dermatophytes, Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis.
Carrillo-Muñoz AJ; Giusiano G; Guarro J; Quindós G; Guardia C; del Valle O; Rodríguez V; Estivill D; Cárdenes CD
Int J Antimicrob Agents; 2007 Aug; 30(2):157-61. PubMed ID: 17555945
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
6. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies.
Espinel-Ingroff A; Johnson E; Hockey H; Troke P
J Antimicrob Chemother; 2008 Mar; 61(3):616-20. PubMed ID: 18222957
[TBL] [Abstract][Full Text] [Related]
7. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of Mexican isolates of yeasts and moulds to amphotericin B and triazole antifungals.
Arredondo-García JL; Amábile-Cuevas CF;
J Infect Dev Ctries; 2009 Jun; 3(5):398-401. PubMed ID: 19759511
[TBL] [Abstract][Full Text] [Related]
9. In vitro antifungal activity of Indian liposomal amphotericin B against clinical isolates of emerging species of yeast and moulds, and its comparison with amphotericin B deoxycholate, voriconazole, itraconazole and fluconazole.
Rudramurthy SM; Jatana M; Singh R; Chakrabarti A
Mycoses; 2013 Jan; 56(1):39-46. PubMed ID: 22519679
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan.
Yamazaki T; Inagaki Y; Fujii T; Ohwada J; Tsukazaki M; Umeda I; Kobayashi K; Shimma N; Page MG; Arisawa M
Int J Antimicrob Agents; 2010 Oct; 36(4):324-31. PubMed ID: 20674282
[TBL] [Abstract][Full Text] [Related]
11. Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi.
Marco F; Pfaller MA; Messer SA; Jones RN
Med Mycol; 1998 Dec; 36(6):433-6. PubMed ID: 10206756
[TBL] [Abstract][Full Text] [Related]
12. Antifungal activity of the new azole UK-109, 496 (voriconazole).
Kappe R
Mycoses; 1999; 42 Suppl 2():83-6. PubMed ID: 10865910
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis.
Bueno JG; Martinez C; Zapata B; Sanclemente G; Gallego M; Mesa AC
Clin Exp Dermatol; 2010 Aug; 35(6):658-63. PubMed ID: 19874354
[TBL] [Abstract][Full Text] [Related]
14. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Meis JF; Gould IM; Fu W; Colombo AL; Rodriguez-Noriega E;
J Clin Microbiol; 2007 Jun; 45(6):1735-45. PubMed ID: 17442797
[TBL] [Abstract][Full Text] [Related]
15. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
Espinel-Ingroff A
J Clin Microbiol; 2001 Mar; 39(3):954-8. PubMed ID: 11230410
[TBL] [Abstract][Full Text] [Related]
16. Voriconazole susceptibilities of dermatophyte isolates obtained from a worldwide tinea capitis clinical trial.
Ghannoum M; Isham N; Sheehan D
J Clin Microbiol; 2006 Jul; 44(7):2579-80. PubMed ID: 16825385
[TBL] [Abstract][Full Text] [Related]
17. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
Espinel-Ingroff A
Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of voriconazole against selected fungi.
McGinnis MR; Pasarell L; Sutton DA; Fothergill AW; Cooper CR; Rinaldi MG
Med Mycol; 1998 Aug; 36(4):239-42. PubMed ID: 9776841
[TBL] [Abstract][Full Text] [Related]
19. In vitro susceptibility patterns of Aspergillus and Fusarium species isolated from equine ulcerative keratomycosis cases in the midwestern and southern United States with inclusion of the new antifungal agent voriconazole.
Pearce JW; Giuliano EA; Moore CP
Vet Ophthalmol; 2009; 12(5):318-24. PubMed ID: 19751493
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study).
Swinne D; Watelle M; Van der Flaes M; Nolard N
Mycoses; 2004 Jun; 47(5-6):177-83. PubMed ID: 15189180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
